Patients with early-stage breast cancer treated with aromatase inhibitors often experience adverse events that lead to discontinuation. In this phase 3 study, researchers sought to determine if duloxetine could manage these symptoms.
Researchers investigated the incidence of lymphedema on patients with breast cancer treated with TAC after axillary lymph node dissection (ALND), with or without radiotherapy, and its impact on quality of life for patients.
Just over half of patients in a standard therapy group had normal bone mineral density after a mean follow-up of 6 years; this contrasted with 93% of patients in a vitamin D supplementation group.
Follow-up of a 2-year analysis of the ExteNET phase 3 study demonstrates the influence of 1-year extended adjuvant therapy with neratinib on relapse in patients with breast cancer 5.2 years after treatment.
In this analysis, researchers measured the impact and effectiveness of supportive treatments for moderate to severe anemia in patients with lymphoma or multiple myeloma, based on patient-reported outcomes.